Cellectis
CLLS
44 hedge funds and large institutions have $213M invested in Cellectis in 2015 Q1 according to their latest regulatory filings, with 44 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.51% more ownership
Funds ownership: 0% → 13.51% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$125M |
| 2 |
JP Morgan Chase
New York
|
+$10.9M |
| 3 |
OrbiMed
New York
|
+$10.9M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.9M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$8.89M |
Top Sellers
CLLS Hedge Fund Activity: Q1 2015 in Review
44 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Cellectis (CLLS) for Q1 2015, worth a combined $213M.
Buyers outnumbered sellers: 44 funds opened new CLLS positions and 0 closed out — a net gain of 44 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $125M.
- 44 institutional investors held Cellectis (CLLS) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $213M of Cellectis stock for Q1 2015.
- 44 funds opened new Cellectis positions in Q1 2015 and 0 closed out, a net change of +44 holders.
- The largest Cellectis buyer in Q1 2015 was Fidelity Investments, an estimated $125M added.
Based on aggregated 13F filings for Q1 2015.